GSK pledges $30bn US investment as UK's pharma woes deepen
Summary
British company GSK plans to invest $30 billion in the U.S. over five years for research and manufacturing. The funds will develop U.S. factories, artificial intelligence tools, and research labs. This announcement comes as drug companies face U.S. pressure to move production there.Key Facts
- GSK will invest $30 billion in the U.S. for research and manufacturing.
- The investment aims to develop factories, AI, and research labs in the U.S.
- A new factory in Pennsylvania will focus on medicines for respiratory diseases and cancer.
- The investment is part of a broader trend where pharma firms redirect spending from the UK to the U.S.
- GSK's investment continues amid U.S. tariffs on pharmaceutical imports.
- Other pharmaceutical companies like Merck and AstraZeneca have also reduced investment in the UK.
- British Prime Minister noted the investment as a positive example of U.S.-UK collaboration.
- Construction for the Pennsylvania factory is expected to start next year.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.